The company has also established the world’s largest datasets and knowledge base on an area of precision cancer medicines called synthetic lethality, totalling more than 80 billion data points and tens of thousands of experimentally validated disease-driving gene combinations. 

With a growing maturation in the research ecosystem in Asia and a significant increase in interest in Asian biotechnology and healthcare, more breakthroughs can be expected in the near future. “Asia comprises half of the world’s population, with different genetics and disease profiles, so precision medicine will necessarily have unique aspects,” says Lu. “The biotechnology industry has never been more vibrant, diverse, and well-positioned to deliver impact.”

Franklin Biotechnology Discovery Fund

The single industry-focused fund invests in companies and research firms that specialise in emerging pharmaceuticals, medical technology and life science tools. Launched in 2000, it seeks potential growth from the biotechnology sector, driven by new drug innovations and long-term healthcare demand from trends such as an aging population.

For more information on Franklin Templeton's investment philosophy and its funds, visit franklintempleton.com.sg.

This advertisement or publication has not been reviewed by the Monetary Authority of Singapore.
The Fund is a sub-fund of Franklin Templeton Investment Funds ("FTIF"), a Luxembourg registered SICAV.
This document is for information only and does not constitute investment advice or a recommendation and was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it. Any research and analysis contained in this document has been procured by Franklin Templeton for its own purposes and may be acted upon in that connection and, as such, is provided to you incidentally. Although information has been obtained from sources that Franklin Templeton believes to be reliable, no guarantee can be given as to its accuracy and such information may be incomplete or condensed and may be subject to change at any time without notice. Any views expressed are the views of the fund manager as of the date of this document and do not constitute investment advice. The underlying assumptions and these views are subject to change based on market and other conditions and may differ from other portfolio managers or of the firm as a whole. There is no assurance that any prediction, projection or forecast on the economy, stock market, bond market or the economic trends of the markets will be realized. Franklin Templeton accepts no liability whatsoever for any direct or indirect consequential loss arising from the use of any information, opinion or estimate herein.
The value of investments and the income from them can go down as well as up and you may not get back the full amount that you invested. Investors may wish to seek advice from a financial adviser before making a commitment to invest in shares of the Fund. In the event an investor chooses not to seek advice from a financial adviser, he/she should consider whether the Fund is suitable for him/her.
Issued by Templeton Asset Management Ltd. Registration Number (UEN) 199205211E.